Deregulation of mitochondrial gene expression in cancer: mechanisms and therapeutic opportunities

• Published in: British journal of cancer Vol. 131; no. 9; pp. 1415 - 1424
• Main Authors: Berner, Mariah J., Wall, Steven W., Echeverria, Gloria V.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 16.11.2024; Nature Publishing Group
• Subjects: 631/67/1059/602; 631/67/2327; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Cancer therapies; Copy number; Drug Resistance; Energy metabolism; Epidemiology; Epigenetics; Gene expression; Gene regulation; Homeostasis; Metabolism; Mitochondria; Mitochondrial DNA; Molecular Medicine; Oncology; Organelles; Phenotypes; Review Article; Toxicity; Transcription factors
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/s41416-024-02817-1

“Reprogramming of energy metabolism” was first considered an emerging hallmark of cancer in 2011 by Hanahan & Weinberg and is now considered a core hallmark of cancer. Mitochondria are the hubs of metabolism, crucial for energetic functions and cellular homeostasis. The mitochondrion’s bacterial origin and preservation of their own genome, which encodes proteins and RNAs essential to their function, make them unique organelles. Successful generation of mitochondrial gene products requires coordinated functioning of the mitochondrial ‘central dogma,’ encompassing all steps necessary for mtDNA to yield mitochondrial proteins. Each of these processes has several levels of regulation, including mtDNA accessibility and protection through mtDNA packaging and epigenetic modifications, mtDNA copy number through mitochondrial replication, mitochondrial transcription through mitochondrial transcription factors, and mitochondrial translation through mitoribosome formation. Deregulation of these mitochondrial processes in the context of cancers has only recently been appreciated, with most studies being correlative in nature. Nonetheless, numerous significant associations of the mitochondrial central dogma with pro-tumor phenotypes have been documented. Several studies have even provided mechanistic insights and further demonstrated successful pharmacologic targeting strategies. Based on the emergent importance of mitochondria for cancer biology and therapeutics, it is becoming increasingly important that we gain an understanding of the underpinning mechanisms so they can be successfully therapeutically targeted. It is expected that this mechanistic understanding will result in mitochondria-targeting approaches that balance anticancer potency with normal cell toxicity. This review will focus on current evidence for the dysregulation of mitochondrial gene expression in cancers, as well as therapeutic opportunities on the horizon.